VivoSeq
Other

Proteinuria

40

Pipeline Programs↗

8

Active Trials↗

23

Companies Involved↗

Proteinuria is a moderately active landscape with 40 programs across 23 companies. The most active players are SynAct Pharma Aps, Bristol-Myers Squibb, Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. 16 therapies are approved with 8 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

57/100

Pipeline Velocity

19/100

Mech. Concentration

21/100

Completion Rate

88/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

SynAct Pharma Aps

1 program

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 2P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Phase 2Q

Qidong Gaitianli Medicines Co., Ltd

1 program

Phase 2Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 2B

Bukwang Pharmaceutical

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

96%

Small molecule

43 of 45 classified programs — the dominant modality here.

4%ALL OTHERSMonoclonal antibody12%Protein / enzyme12%

Small molecule leads; the ring shows all 45 classified programs, each share of the total. Modality classified for 100% of 48 pipeline programs.

Analysis

Trial Status

38

clinical trials

Completed21 · 55%
Unknown status6 · 16%
Recruiting3 · 8%
Active, not recruiting3 · 8%
Withdrawn2 · 5%
Not yet recruiting2 · 5%
Other1 · 3%

Clinical Trials

Trial Activity

38 trials

A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria
Recruiting·SSynAct Pharma Aps·Phase 2·NCT04456816·23 enrolled
Effect of Sodium-glucose Cotransporter-2 Inhibitors (SGLT-2i) on Proteinuria in Nephrotic Children Older Than 10 Years
Recruiting·MMansoura University·Phase 4·NCT06417320·60 enrolled
Finerenone Therapy for Pediatric HSPN With Mild Proteinuria
Recruiting·—·Phase 4·NCT07315191·116 enrolled
FINEPKT - Finerenone in Proteinuria Patients After Kidney Transplan
Active, not recruiting·—·Phase 3·NCT07356388·54 enrolled
Efficacy and Safety of Dapagliflozin in Children With Proteinuria
Active, not recruiting·—·N/A·NCT07204743·10 enrolled
A Multicenter, Open-label Single Arm Study to Evaluate the Safety and Efficacy of Sparsentan in Posttransplant Immunoglobulin A Nephropathy (IgAN) or Focal Segmental Glomerulosclerosis (FSGS) (SPARX)
Active, not recruiting·TTravere Therapeutics, Inc.·Approved·NCT07219121·20 enrolled
Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria
Not yet recruiting·—·Phase 1·NCT07224776·20 enrolled
Huaier Granule and Proteinuria
Not yet recruiting·FFudan University·Phase 2·NCT07355361·120 enrolled
Influence of Aliskiren on Proteinuria
Completed·MMedical University of Gdansk·Phase 4·NCT01219413·16 enrolled
Soluble CD146 and Proteinuria in Chronic Renal Disease
Completed·AAssistance Publique Hopitaux De Marseille·N/A·NCT03341949·204 enrolled
The Effect of Various Types of the Renin-angiotensin-aldosterone System Blockade on Proteinuria
Completed·MMedical University of Gdansk·Phase 4·NCT01541267·20 enrolled
Prospective Study of TW in the Treatment of LN Type V With Gross Proteinuria
Completed·NNanjing University School of Medicine·N/A·NCT00935389·44 enrolled
Effect of Pentoxifylline on Proteinuria in Korean Type 2 Diabetic Patients
Completed·—·Phase 4·NCT01382303·174 enrolled
Use of Mucomyst to Ameliorate Oxidant Stress in Diabetics With Proteinuria
Completed·US Department of Veterans Affairs·N/A·NCT00493727·15 enrolled
Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria
Completed·AstraZeneca logoAstraZeneca·Phase 1·NCT05314231·13 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)